Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production

The mineralocorticoid receptor (MR) is expressed in kidney and plays a central role in the control of sodium, homeostatic fluid, and blood pressure. It has also been implicated in other functions in cardiovascular system, central nervous system, and adipose tissue. This study revealed a novel role o...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2006-04, Vol.342 (4), p.1291-1296
Main Authors: Liu, GuoHong, Grifman, Mirta, Keily, Benjamin, Chatterton, Jon E., Staal, Flossie-Wong, Li, Qi-Xiang
Format: Article
Language:English
Subjects:
Cells, Cultured
Gene Expression Regulation - physiology
Glucose - biosynthesis
Glucose-6-phosphatase
Glucose-6-Phosphatase - metabolism
Hepatic glucose output
Humans
Liver - metabolism
Mineralocorticoid receptor
Nuclear receptor
Receptors, Mineralocorticoid - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mineralocorticoid receptor (MR) is expressed in kidney and plays a central role in the control of sodium, homeostatic fluid, and blood pressure. It has also been implicated in other functions in cardiovascular system, central nervous system, and adipose tissue. This study revealed a novel role of MR in the gene regulation related to hepatic glucose production. RNAi-mediated MR silencing led to a decrease in the expression of glucose-6-phosphatase (G6Pase), phosphoenolpyruvate carboxykinase, and fructose-1,6-bisphosphatase 1, the enzymes known to be involved in glucose production in liver. The MR-specific antagonists also down-regulated the expression of G6Pase, while the specific agonist enhanced G6Pase expression. These observations, for the first time, revealed a novel role for MR and its ligands in the regulation of de novo glucose synthesis in hepatocytes. It also suggests the potential of liver-specific MR modulation for the treatment of hyperglycemia.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2006.02.065